Fig. 11From: The impact of additive or substitutive clinical study design on the negotiated reimbursement for oncology pharmaceuticals after early benefit assessment in GermanyPotential Budget Impact. The figure shows the potential budget impact of new oncology products assuming a complete uptake of the products with regard to the whole target population, which is reflected by the respective prevalence of the subgroup-weighted indicationsBack to article page